Targets › CTXM
1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease; next expected readout Apr 2027.
Open in Phaseline: the race on CTXM, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pfizer | aztreonam-avibactam (ATM-AVI) β-lactam antibiotic (aztreonam) combined with β-lactamase inhibitor (avibactam) | MMPBLA, CTXM | Phase 2 | Gram-negative Bacterial Infection | Apr 2027 |
Gram-negative Bacterial Infection (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.